Cita APA

Diamond, E. L., Subbiah, V., Lockhart, A. C., Blay, J., Puzanov, I., Chau, I., . . . Hyman, D. M. (2017). Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol.

Chicago Style Citation

Diamond, Eli L., et al. "Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study." JAMA Oncol 2017.

Cita MLA

Diamond, Eli L., et al. "Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study." JAMA Oncol 2017.